Evie Wren

Evie Wren

Auto-generated profile, based on publicly available information

Evie Wren

Department of Surgery and Cancer Imperial College London, Hammersmith Hospital Campus London UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2024 in JCO Precision Oncology
Verified
Journal Article
Open access
JSJacqui Shaw
Jacqui Shaw
KPKaren Page
Karen Page
EWEvie Wren
Evie Wren
EBElza C. de Bruin
Elza C. de Bruin
EKEkaterina Kalashnikova
Ekaterina Kalashnikova
RCR. Charles Coombes
R. Charles Coombes
PURPOSE: Here, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection of molecular relapse during long-term follow-up of patients with breast cancer. METHODS: A total of 156 patients with primary breast cancer were monitored clinically for up to 12 years after surgery and adjuvant chemotherapy. Semiannual blood samples were prospectively collected, and analyzed retrospectively to detect residual disease by ultradeep sequencing using ctDNA assays, developed from primary tumor whole-exome sequencing data. RESULTS: Personalized Signatera assays detected ctDNA ahead of clinical or radiologic relapse in 30 of the 34 patients who relapsed (patient-level sensitivity of 88.2%). Relapse was predicted with a lead interval of up to 38 months (median, 10.5 months; range, 0-38 months), and ctDNA positivity was associated with shorter relapse-free survival ( P < .0001) and overall survival ( P < .0001). All relapsing triple-negative patients (n = 7/23) had a ctDNA-positive test within a median of 8 months (range, 0-19 months), while the 16 nonrelapsed patients with triple-negative breast cancer remained ctDNA-negative during a median follow-up of 58 months (range, 8-99 months). The four patients who had negative tests before relapse all had hormone receptor–positive (HR+) disease and conversely, five of the 122 nonrelapsed patients (all HR+) had an occasional positive test. CONCLUSION: Serial postoperative ctDNA assessment has strong prognostic value, provides a potential window for earlier therapeutic intervention, and may enable more effective monitoring than current clinical tests such as cancer antigen 15-3. Our study provides evidence that those with serially negative ctDNA tests have superior clinical outcomes, providing reassurance to patients with breast cancer. For select cases with HR+ disease, decisions about treatment management might require serial monitoring despite the ctDNA-positive result.

3 February 2026 in Chemical & Biomedical Imaging
Verified
Journal Article
Open access
ALAmy V. Lovejoy
Amy V. Lovejoy
AMAlexander P. Morrell
Alexander P. Morrell
Diego MesaDiego Mesa
Diego Mesa
AGAlex Griffiths
Alex Griffiths
PGPiotr R. Golda
Piotr R. Golda
RMRebekah Elizabeth Thorne Moore
Rebekah Elizabeth Thorne Moore
Trace metal homeostasis is critical for cellular function and often disrupted in diseases such as cancer. Spatially resolved techniques enable mapping of metal distributions within complex cellular environments, surpassing the limitations of bulk analyses. Formalin-fixed, paraffin-embedded (FFPE) tissues are widely used in research, yet the impact of FFPE processing on endogenous elemental contents and distributions remains unclear, with conflicting findings across sample types. This study evaluates the suitability of FFPE human breast carcinoma tissue sections for multielemental bioimaging by direct comparison with paired fresh frozen (FF) tissues and assesses potential sources of contamination or elemental losses during processing. Three FF human breast carcinoma specimens were bisected and processed as either FF or FFPE. Serial sections underwent analyses by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS), alongside hematoxylin and eosin (H&E)-staining, to compare elemental profiles in whole sections and morphologically distinct regions. In parallel, FFPE processing reagents encompassing tissue-marking dyes, formalin, paraffin wax, xylene, and ethanol were analyzed via solution ICP-MS to contextualize the in situ findings. The multielemental imaging results revealed that Zn, Mn, and Fe were largely preserved in FFPE sections, supporting the continued use of such tissues for in situ metal analyses. Addition of Cu was observed for all FFPE samples, most likely caused by exposure to blue tissue-marking dye. Formalin induced variable elemental leaching, most notably affecting Mg. Paraffin wax, ethanol, and xylene contained minimal trace metal levels both before and after contact with tissues.

27 October 2025 in The Journal of Pathology
Verified
Journal Article
Open access
GNGeorgios Nteliopoulos
Georgios Nteliopoulos
EWEvie Wren
Evie Wren
ARAmelia Rushton
Amelia Rushton
MWMarc K Wadsley
Marc K Wadsley
DFDaniel Fernandez‐Garcia
Daniel Fernandez‐Garcia
RCR Charles Coombes
R Charles Coombes
Formalin‐fixed paraffin‐embedded (FFPE) tissue specimens represent precious resources for clinical genomic profiling studies, especially when coupled with comprehensive medical records. Even though next‐generation sequencing (NGS) is an effective tool to detect somatic mutations and somatic copy number alterations (sCNA), the biggest challenges in unlocking clinically translatable genomic information from FFPE tissue are low DNA yields and degraded DNA, affected by variable formalin fixation. Another issue is that the proportion of carcinoma and other noncarcinoma cells is variable and can be confounded by intratumoral heterogeneity. To explore these challenges, we isolated pure carcinoma and stromal cells using the DEPArray™ NxT system, a microchip‐based digital sorter that allows isolation of pure, homogeneous subpopulations of cells from FFPE samples. We isolated pure carcinoma and stromal cell populations from 12 FFPE tissues, including tissues from nine primary and metastatic breast cancer and three primary ovarian high‐grade serous carcinomas. This was followed by downstream shallow whole‐genome sequencing (WGS) for copy number landscape profiling (10 samples) and/or a targeted panel for somatic mutation and sCNA analysis (seven samples), subject to cell availability. Seven out of 10 samples (even some with low tumour content or of old age) produced good‐quality genomic data, detecting sCNA in all carcinoma population samples but not in the stromal populations. Mutation analysis was performed successfully in 6/7 samples and somatic mutations were detected in all of them. Our workflow enabled the identification of clinically actionable targets, including PIK3CA, ERBB2, FGFR1/2, CDK6, CCNE1, KRAS amplifications and RB, BRCA1/2 losses in patients that would direct therapy. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.